Thanks for the warm welcome Antibody. And apologies for the initial short post.
I follow MSB closely although I hold no stock. MSB are polarising. I find the differences between Collies and Roberts reports fascinating. I struggle with MSBs lack of reporting of preclinical and clinical data. I believe strongly that stem cells will be successful but doubt that one cell type will meet all the market needs.
The fresh verses frozen article is extremely relevant to MSB. Particularly to Prochymal as the study described is in graft verses host disease. It suggests that off-the-shelf stem cell products are going to need further development before they are successful. The cryopreservation methods haven’t changed for decades. Is MSB capable of overcoming these challenges? Not in-house their not. I don’t see reports of new technology or patents coming out of MSB. In my view, they should be aggressively acquiring technologies in this space.
MSB Price at posting:
$5.28 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)